The CHDI Foundation, a privately-funded nonprofit research organization dedicated to fighting Huntington’s disease, has awarded a research grant to…
Articles by Ana de Barros, PhD
Teva Pharmaceutical presented encouraging top-line data from PRIDE-HD, a Phase 2 clinical trial evaluating the impact of pridopidine, an oral…
Voyager Therapeutics has partnered with the CHDI Foundation to advance its VY-HTT01 gene-silencing therapy for Huntington’s disease (HD). The…
Vaccinex‘s VX15, a novel clinical stage monoclonal antibody for Huntington’s disease (HD) treatment, has been granted Fast Track designation by the U.S.
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to WAVE Life Sciences‘ lead candidate WVE-120101, which is…
Teva Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) answering the pharmaceutical’s…
During the 68th American Academy of Neurology (AAN) meeting in Vancouver, Teva Pharmaceutical Industries Ltd. presented new results…
A professor at Washington University in St. Louis, Missouri, has been awarded two grants from the National Institutes of Health (NIH) totaling…
The Weill Family Foundation and Joan and Sanford I. “Sandy” Weill have donated $185,000,000 to the University of California,…
Powerful artificial lights, known as Lumie lamps, are being donated to neurologists at Cambridge University’s School of Clinical Medicine for a research…